Publication

High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Kain, R., Tadema, H., McKinney, E. F., Benharkou, A., Brandes, R., Peschel, A., Hubert, V., Feenstra, T., Sengoelge, G., Stegeman, C., Heeringa, P., Lyons, P. A., Smith, K. G. C., Kallenberg, C. & Rees, A. J., Mar-2012, In : Journal of the American Society of Nephrology. 23, 3, p. 556-566 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Kain, R., Tadema, H., McKinney, E. F., Benharkou, A., Brandes, R., Peschel, A., ... Rees, A. J. (2012). High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Journal of the American Society of Nephrology, 23(3), 556-566. https://doi.org/10.1681/ASN.2011090920

Author

Kain, Renate ; Tadema, Henko ; McKinney, Eoin F. ; Benharkou, Alexandra ; Brandes, Ricarda ; Peschel, Andrea ; Hubert, Virginie ; Feenstra, Tjerk ; Sengoelge, Guerkan ; Stegeman, Coen ; Heeringa, Peter ; Lyons, Paul A. ; Smith, Kenneth G. C. ; Kallenberg, Cees ; Rees, Andrew J. / High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. In: Journal of the American Society of Nephrology. 2012 ; Vol. 23, No. 3. pp. 556-566.

Harvard

Kain, R, Tadema, H, McKinney, EF, Benharkou, A, Brandes, R, Peschel, A, Hubert, V, Feenstra, T, Sengoelge, G, Stegeman, C, Heeringa, P, Lyons, PA, Smith, KGC, Kallenberg, C & Rees, AJ 2012, 'High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis' Journal of the American Society of Nephrology, vol. 23, no. 3, pp. 556-566. https://doi.org/10.1681/ASN.2011090920

Standard

High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. / Kain, Renate; Tadema, Henko; McKinney, Eoin F.; Benharkou, Alexandra; Brandes, Ricarda; Peschel, Andrea; Hubert, Virginie; Feenstra, Tjerk; Sengoelge, Guerkan; Stegeman, Coen; Heeringa, Peter; Lyons, Paul A.; Smith, Kenneth G. C.; Kallenberg, Cees; Rees, Andrew J.

In: Journal of the American Society of Nephrology, Vol. 23, No. 3, 03.2012, p. 556-566.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Kain R, Tadema H, McKinney EF, Benharkou A, Brandes R, Peschel A et al. High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Journal of the American Society of Nephrology. 2012 Mar;23(3):556-566. https://doi.org/10.1681/ASN.2011090920


BibTeX

@article{3cb81c03fede4c7fa3d2b6e1da6026e4,
title = "High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
abstract = "The involvement of autoantibodies to human lysosome-associated membrane protein-2 (hLAMP-2) in anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis is controversial because of the absence of confirmatory data subsequent to the initial reports of their high prevalence in this disease. We characterized three assays for anti-hLAMP-2 antibodies: ELISA and Western blotting assays using unglycosylated recombinant hLAMP-2 expressed in Escherichia coli, and an indirect immunofluorescence assay using stably transfected IdID cells that expressed glycosylated full-length hLAMP-2 on the plasma membrane. The assays detected autoantibodies to hLAMP-2 in human sera reproducibly and with comparable sensitivity and the assays gave the same results in 80.5{\%} of the test panel of 40 selected positive and negative sera. In untreated patients at presentation, the frequencies of autoantibodies to LAMP-2 were 89{\%}, 91{\%}, and 80{\%}, respectively, among three groups of patients with ANCA-associated vasculitis from Vienna, Austria (n=19); Groningen, the Netherlands (n=50) and Cambridge, United Kingdom (n=53). Prevalence of LAMP-2 autoantibodies was similar in both those with myeloperoxidase-ANCA and proteinase 3-ANCA. Furthermore, we detected LAMP-2 autoantibodies in two ANCA-negative patients. LAMP-2 autoantibodies rapidly became undetectable after the initiation of immunosuppressive treatment and frequently became detectable again during clinical relapse. We conclude that when robust assays are used, circulating autoantibodies to hLAMP-2 can be detected in most European patients with ANCA-associated vasculitis. Large-scale prospective studies are now needed to determine whether they are pathogenic or merely an epiphenomenon.",
keywords = "CRESCENTIC GLOMERULONEPHRITIS, ENDOTHELIAL-CELLS, MEMBRANE-PROTEIN, GRANULOCYTES, H-LAMP-2, RECEPTOR, MICE",
author = "Renate Kain and Henko Tadema and McKinney, {Eoin F.} and Alexandra Benharkou and Ricarda Brandes and Andrea Peschel and Virginie Hubert and Tjerk Feenstra and Guerkan Sengoelge and Coen Stegeman and Peter Heeringa and Lyons, {Paul A.} and Smith, {Kenneth G. C.} and Cees Kallenberg and Rees, {Andrew J.}",
year = "2012",
month = "3",
doi = "10.1681/ASN.2011090920",
language = "English",
volume = "23",
pages = "556--566",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "AMER SOC NEPHROLOGY",
number = "3",

}

RIS

TY - JOUR

T1 - High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

AU - Kain, Renate

AU - Tadema, Henko

AU - McKinney, Eoin F.

AU - Benharkou, Alexandra

AU - Brandes, Ricarda

AU - Peschel, Andrea

AU - Hubert, Virginie

AU - Feenstra, Tjerk

AU - Sengoelge, Guerkan

AU - Stegeman, Coen

AU - Heeringa, Peter

AU - Lyons, Paul A.

AU - Smith, Kenneth G. C.

AU - Kallenberg, Cees

AU - Rees, Andrew J.

PY - 2012/3

Y1 - 2012/3

N2 - The involvement of autoantibodies to human lysosome-associated membrane protein-2 (hLAMP-2) in anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis is controversial because of the absence of confirmatory data subsequent to the initial reports of their high prevalence in this disease. We characterized three assays for anti-hLAMP-2 antibodies: ELISA and Western blotting assays using unglycosylated recombinant hLAMP-2 expressed in Escherichia coli, and an indirect immunofluorescence assay using stably transfected IdID cells that expressed glycosylated full-length hLAMP-2 on the plasma membrane. The assays detected autoantibodies to hLAMP-2 in human sera reproducibly and with comparable sensitivity and the assays gave the same results in 80.5% of the test panel of 40 selected positive and negative sera. In untreated patients at presentation, the frequencies of autoantibodies to LAMP-2 were 89%, 91%, and 80%, respectively, among three groups of patients with ANCA-associated vasculitis from Vienna, Austria (n=19); Groningen, the Netherlands (n=50) and Cambridge, United Kingdom (n=53). Prevalence of LAMP-2 autoantibodies was similar in both those with myeloperoxidase-ANCA and proteinase 3-ANCA. Furthermore, we detected LAMP-2 autoantibodies in two ANCA-negative patients. LAMP-2 autoantibodies rapidly became undetectable after the initiation of immunosuppressive treatment and frequently became detectable again during clinical relapse. We conclude that when robust assays are used, circulating autoantibodies to hLAMP-2 can be detected in most European patients with ANCA-associated vasculitis. Large-scale prospective studies are now needed to determine whether they are pathogenic or merely an epiphenomenon.

AB - The involvement of autoantibodies to human lysosome-associated membrane protein-2 (hLAMP-2) in anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis is controversial because of the absence of confirmatory data subsequent to the initial reports of their high prevalence in this disease. We characterized three assays for anti-hLAMP-2 antibodies: ELISA and Western blotting assays using unglycosylated recombinant hLAMP-2 expressed in Escherichia coli, and an indirect immunofluorescence assay using stably transfected IdID cells that expressed glycosylated full-length hLAMP-2 on the plasma membrane. The assays detected autoantibodies to hLAMP-2 in human sera reproducibly and with comparable sensitivity and the assays gave the same results in 80.5% of the test panel of 40 selected positive and negative sera. In untreated patients at presentation, the frequencies of autoantibodies to LAMP-2 were 89%, 91%, and 80%, respectively, among three groups of patients with ANCA-associated vasculitis from Vienna, Austria (n=19); Groningen, the Netherlands (n=50) and Cambridge, United Kingdom (n=53). Prevalence of LAMP-2 autoantibodies was similar in both those with myeloperoxidase-ANCA and proteinase 3-ANCA. Furthermore, we detected LAMP-2 autoantibodies in two ANCA-negative patients. LAMP-2 autoantibodies rapidly became undetectable after the initiation of immunosuppressive treatment and frequently became detectable again during clinical relapse. We conclude that when robust assays are used, circulating autoantibodies to hLAMP-2 can be detected in most European patients with ANCA-associated vasculitis. Large-scale prospective studies are now needed to determine whether they are pathogenic or merely an epiphenomenon.

KW - CRESCENTIC GLOMERULONEPHRITIS

KW - ENDOTHELIAL-CELLS

KW - MEMBRANE-PROTEIN

KW - GRANULOCYTES

KW - H-LAMP-2

KW - RECEPTOR

KW - MICE

U2 - 10.1681/ASN.2011090920

DO - 10.1681/ASN.2011090920

M3 - Article

VL - 23

SP - 556

EP - 566

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 3

ER -

ID: 5517228